Printed from Voxsanity (voxsanity.com.au) — NCT07120451 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Ovarian Cancer
Phase 2 Ovarian Cancer Trial, Not Yet Recruiting
NCT07120451
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- People who are willing to take part voluntarily, have signed a consent form, are able to follow the study requirements, and are willing to attend follow-up appointments.
- People aged between 18 and 75 years old (calculated from the date the consent form is signed).
- People who have been newly diagnosed with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer, confirmed by laboratory examination of tissue samples.
- People with an advanced stage of the disease (FIGO stage III or IV): those with stage III must have had one surgery to remove as much of the tumour as possible; those with stage IV must have had a biopsy and/or tumour-removal surgery; and all participants must be able to provide 10 tissue sample slides for research purposes.
- People whose tumour has been tested and found to be HRP (a specific biological marker — confirm with trial site).
- People whose cancer has responded to platinum-based chemotherapy, either with no detectable signs of disease remaining (complete response) or with a measurable reduction in the tumour (partial response), as defined by specific medical imaging and blood test standards.
- People whose CA125 blood test results (a marker linked to ovarian cancer) meet specific criteria before treatment: if the first result is within the normal range, no second test is needed; if the first result is above the normal range, a second test must be done at least 7 days later, and the second result must not be 15% or more higher than the first.
- People who are enrolled and begin the trial treatment within 8 to 12 weeks after their last chemotherapy session.
- People with an ECOG performance score of 0 or 1, meaning they are fully active or have only minor restrictions on physical activity (confirm with trial site).
- People whose major organ functions are within acceptable ranges, based on blood tests taken without blood products or growth factor treatments in the 14 days before enrolment, including: sufficient levels of haemoglobin, neutrophils, and platelets; liver enzyme and bilirubin levels within acceptable limits; and kidney function within acceptable limits.
- People with the ability to have children who agree to use at least one medically approved form of contraception during treatment and for 6 months after the last dose, who have a negative pregnancy blood test within 72 hours before the first dose, and who are not breastfeeding.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have had another cancer in the past 5 years, or who currently have another cancer that cannot be cured — exceptions may apply for certain treated skin cancers, thyroid cancer, cervical pre-cancer, or breast cancer with no recurrence for more than 3 years after completed treatment.
- People who have previously used PARP inhibitor medicines (a specific type of cancer drug — confirm with trial site).
- People who are unable to swallow tablets normally, or who have digestive system problems that researchers believe could affect how the study drug is absorbed.
- People who have had a hole form in their digestive tract, or major surgery, within the 4 weeks before the first dose; or people who have had a serious bleeding event, or who have wounds, ulcers, or fractures that have not healed.
- People whose medical imaging (CT or MRI scan) shows the tumour is growing into large blood vessels or has unclear boundaries with blood vessels.
- People whose blood pressure is not well controlled (systolic pressure at or above 150 mmHg and/or diastolic pressure at or above 90 mmHg).
- People whose urine test shows elevated protein levels, confirmed by a 24-hour urine collection showing 1.0 g or more of protein.
- People who have had a bowel obstruction in the past 3 months.
- People who have cancer-related fluid build-up in the abdomen or chest that is causing symptoms requiring draining, or who have had such fluid drained within 2 months before the first trial dose.
- People with abnormal blood clotting function, a tendency to bleed, or who are receiving clot-dissolving or blood-thinning treatments — noting that low-dose preventive blood-thinning treatment may be permitted during the trial (confirm with trial site).
- People who have taken part in another clinical drug trial within the previous 4 weeks.
- People who have taken certain strong medications that affect how the body processes drugs (known as strong CYP3A4 inhibitors or inducers) before the first dose — unless enough time has passed for those medicines to clear the body; these medications are also not permitted during the study (confirm with trial site for the specific list).
- People who receive other systemic cancer treatments during the study period.
- People known to be allergic to any ingredients in Senaparib or Bevacizumab (the study drugs).
- People who, in the researchers' judgement, have other serious conditions — such as significant mental illness, major abnormalities in lab results, or family or social circumstances — that could affect the safety of participation or the reliable collection of study data.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Contact this trial
Phone: 021-64175590
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Phase 2
Sponsor
Registry
ClinicalTrials.gov
Start date
10 October 2025
Est. completion
31 October 2026
Where this trial is recruiting
🇨🇳 China
Primary endpoints
PFS
Can't join this trial?
Data last synced from ClinicalTrials.gov: 31 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.